Resources

Synthetic DNA sequences with fewer constraints on sequence complexity are crucial to drive cell and gene therapies forward. Here’s why.

As the potential of mRNA vaccines to meet a significant, unfulfilled medical demand becomes increasingly clear, we’ll need greater access to gene-length DNA far beyond what’s available right now.

In recent years, there has been significant interest in using an enzyme called Terminal deoxynucleotidyl transferase (TdT) to produce synthetic DNA. If we're a cutting-edge DNA synthesis company, why aren't we using TdT?

We all know by now that the CRISPR-Cas system is nothing short of a revolution for gene editing, but DNA synthesis can’t keep up with CRISPR.

Over recent years the pharmaceutical industry has gradually turned towards synthetic biology to assist with the discovery of new medicines.

To produce a synthetic gene, we first divide it up into smaller pieces of DNA that are synthesised. Genes can be thousands of base pairs long, so there are many different ways to do this.

Following its $10 million Series A financing1 earlier in the year, the appointment forms part of the Company’s growth plans to expand commercialisation of its pioneering DNA synthesis platform, gSynth™.